Multi-Modality Quantitative Imaging for Evaluation of Response to Cancer Therapy

用于评估癌症治疗反应的多模态定量成像

• 批准号: 10437852
• 负责人: Yong Du
• 金额: $ 64.24万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-19 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10437852
• 关键词: Adopted; Adoption; Advanced Malignant Neoplasm; Algorithms; Alkaline Phosphatase; Area; Bone neoplasms; Clinical; Clinical Trials; Data; Development; Evaluation; FOLH1 gene; Financial compensation; Goals; Gold; Grant; Human; Image; Image Analysis; Imaging Device; Institution; Lesion; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of prostate; Measures; Metastatic Neoplasm to the Bone; Methods; Minor; Noise; PET/CT scan; Patients; Positron-Emission Tomography; Prevalence; Prostate Adenocarcinoma; Prostate Cancer therapy; Prostate-Specific Antigen; Protocols documentation; Radionuclide Imaging; Regimen; Serum Markers; Software Tools; Source; System; Technetium Tc 99m Medronate; Techniques; Testing; Time; Translating; Tumor Burden; Tumor Volume; Vendor; Visual; advanced disease; anatomic imaging; anticancer research; automated segmentation; base; bone; bone imaging; cancer therapy; castration resistant prostate cancer; clinical practice; cost; imaging biomarker; imaging modality; imaging study; improved; in vivo; indexing; interest; multimodality; new therapeutic target; novel therapeutics; predicting response; quantitative imaging; quantum; reconstruction; relative cost; response; simulation; single photon emission computed tomography; standard of care; targeted treatment; treatment response; trial comparing; uptake

Bone metastases are common in advanced cancers including prostate adenocarcinoma, where there is evidence of bone metastases in more than 70% of patients with advanced disease. Despite their prevalence and the important clinical implications, there is currently no widely accepted quantitative imaging assessment for response to therapy. Assessment of response or progression is typically made based on visual interpretation of bone scintigraphy in conjunction with CT and serum markers. The goal of this project is thus to develop, validate, and advance to clinical practice multi-modality quantitative metrics for assessing response of bone metastases to therapy. Combined SPECT-CT systems and the implementation of robust compensation methods has enabled the development of quantitative SPECT imaging methods, which have recently become clinically available. Here we propose to exploit the nexus of these developments via the following 3 aims. (1) Using simulation and phantom studies, we will first optimize and evaluate methods for quantitative SPECT/CT (QSPECT) imaging of Tc-99m MDP. We propose to expand the phantom studies to a QIN cooperative project in order to evaluate the methods across different scanners and centers. (2) Based on these QSPECT methods, we will develop, optimize, and characterize quantitative bone SPECT indices for assessing response to therapy. Computing these indices will involve semi-automatic segmentation of bone and bone lesions, implemented in an integrated software tool. The indices calculated will include the number of lesions, bone lesion burden, and change in lesion uptake with therapy. We will characterize the variability of the indices using realistic simulations and in pre-therapy test-retest studies. (3) Finally, we will apply the methods and validate them in current clinical trials of new therapeutic regimens for bone metastatic castrate-resistant prostate cancer. In these studies, we will evaluate the methods in terms of time to progression and will compare the methods in vivo to similar quantitative metrics estimated from Na18F PET/CT. We will also investigate the amount of additional information provided by whole-body MRI and PSMA PET/CT. We will make the methods and images available to the QIN and propose to organize challenges of segmentation and response metrics to take advantage of the QIN-wide interest in these areas. Together, these quantitative imaging tools and studies will provide a validated approach for quantitative imaging-based evaluation of response in bone metastases that is readily clinically implementable with only a minor increase in cost relative to clinical standard bone scintigraphy.

骨转移在包括前列腺腺癌在内的晚期癌症中很常见，其中 超过 70% 的晚期疾病患者存在骨转移的证据。尽管它们很流行 以及重要的临床意义，目前还没有广泛接受的定量成像 评估对治疗的反应。反应或进展的评估通常基于 结合 CT 和血清标记物进行骨闪烁扫描的视觉解释。该项目的目标 因此，就是开发、验证并推进临床实践的多模态定量指标来评估 骨转移对治疗的反应。结合 SPECT-CT 系统和稳健的实施 补偿方法促进了定量 SPECT 成像方法的发展， 最近已进入临床。在这里，我们建议通过以下方式利用这些发展的联系： 以下3个目标。 (1) 通过模拟和模型研究，我们将首先优化和评估方法 Tc-99m MDP 的定量 SPECT/CT (QSPECT) 成像。我们建议将模型研究扩展到 QIN 合作项目，旨在评估不同扫描仪和中心的方法。 (2) 基于这些 QSPECT 方法，我们将开发、优化和表征定量骨 SPECT 评估治疗反应的指标。计算这些指数将涉及半自动 骨和骨病变的分割，在集成软件工具中实现。计算出的指数 将包括病变数量、骨病变负荷以及治疗后病变摄取的变化。我们将 使用现实模拟和治疗前重测研究来表征指数的变异性。 (3) 最后，我们将应用这些方法并在当前新治疗方案的临床试验中进行验证 骨转移性去势抵抗性前列腺癌。在这些研究中，我们将评估这些方法 进展时间，并将体内方法与估计的类似定量指标进行比较 Na18F PET/CT。我们还将调查全身 MRI 提供的附加信息量 和 PSMA PET/CT。我们将向 QIN 提供方法和图像，并建议组织 细分和响应指标的挑战，以利用 QIN 广泛的兴趣 地区。总之，这些定量成像工具和研究将为 基于定量成像的骨转移反应评估，易于临床应用 相对于临床标准骨闪烁扫描，成本仅略有增加即可实施。

项目成果

Noise considerations for PET quantification using maximum and peak standardized uptake value.

使用最大和峰值标准化摄取值进行 PET 定量时的噪声考虑因素。

• DOI: 10.2967/jnumed.111.101733
• 发表时间: 2012-07
• 期刊: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
• 作者: Lodge MA;Chaudhry MA;Wahl RL
• 通讯作者: Wahl RL

Factors affecting the stability and repeatability of gamma camera calibration for quantitative imaging applications based on a retrospective review of clinical data.

• DOI: 10.1186/s13550-014-0067-x
• 发表时间: 2014-12
• 期刊: EJNMMI research
• 影响因子: 3.2
• 作者: Anizan N;Wang H;Zhou XC;Hobbs RF;Wahl RL;Frey EC
• 通讯作者: Frey EC

A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging.

• DOI: 10.1088/0031-9155/57/12/3711
• 发表时间: 2012-06-21
• 期刊: Physics in medicine and biology
• 影响因子: 3.5
• 作者: Rong X;Du Y;Frey EC
• 通讯作者: Frey EC

Quo Vadis: PET and Single-Photon Molecular Breast Imaging.

Quo Vadis：PET 和单光子分子乳腺成像。

• DOI: 10.2967/jnumed.115.159202
• 发表时间: 2016
• 期刊: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
• 作者: Wahl,RichardL

Letter: Design flaws in study of differentiating functional abdominal pain, recurrent acute pancreatitis and chronic pancreatitis via radiomics features. Authors' reply.

信件：通过放射组学特征区分功能性腹痛、复发性急性胰腺炎和慢性胰腺炎的研究存在设计缺陷。

• DOI: 10.1016/j.ejrad.2020.108871
• 发表时间: 2020
• 期刊: European journal of radiology
• 影响因子: 3.3
• 作者: Faghih,Mahya;Singh,VikeshK;Mashayekhi,Rouzbeh;Parekh,VishwaS;Jacobs,MichaelA;Zaheer,Atif
• 通讯作者: Zaheer,Atif